These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23907907)

  • 1. The effect of the renin-angiotensin-aldosterone system inhibition on myocardial function in early and late phases of dilated cardiomyopathy in Tgaq*44 mice.
    Woźniak M; Tyrankiewicz U; Drelicharz L; Skórka T; Jabłońska M; Heinze-Paluchowska S; Chłopicki S
    Kardiol Pol; 2013; 71(7):730-7. PubMed ID: 23907907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
    Connelly KA; Advani A; Advani S; Zhang Y; Thai K; Thomas S; Krum H; Kelly DJ; Gilbert RE
    Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction.
    Pitt B
    Cardiol Clin; 1994 Feb; 12(1):101-14. PubMed ID: 8181019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S; Burkhoff D; Garrelds IM; Boomsma F; Danser AH
    Eur Heart J; 2009 Apr; 30(7):805-12. PubMed ID: 19223317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S; Kitakaze M
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE".
    Ruzicka M; Coletta E; White R; Davies R; Haddad H; Leenen FH
    Am J Hypertens; 2010 Nov; 23(11):1179-82. PubMed ID: 20634797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.